ITCI Intra Cellular Therapies Inc

Intra-Cellular Therapies Inc is a biopharmaceutical company. It is engaged in discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders.

$37.66  -0.21 (-0.54%)
As of 05/14/2021 15:59:58 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/27/2013
Outstanding shares:  81,202,226
Average volume:  578,349
Market cap:   $3,074,316,276
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    46116X101
ISIN:        US46116X1019
Sedol:      BHCB0P4
Valuation   (See tab for details)
PE ratio:   -13.14
PB ratio:   4.98
PS ratio:   82.40
Return on equity:   -28.05%
Net income %:   -460.21%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy